{{medical}}
{{Infobox drug|type=mab|ChemSpiderID=none|bioavailability=|protein_bound=|metabolism=|elimination_half-life=|excretion=|CAS_number=1428935-60-7|PubChem=249565666|IUPHAR_ligand=7985|DrugBank=DB11714|UNII_Ref={{fdacite|correct|FDA}}|ATC_prefix=L01|UNII=28X28X9OKV|KEGG_Ref={{keggcite|correct|kegg}}|KEGG=D10808|synonyms=MEDI4736, MEDI-4736|C=6502|H=10018|N=1742|O=2024|S=42|legal_CN=Rx|ATC_suffix=XC28|routes_of_administration=静脉给药|image=Durvalumab PD-L1 5X8M.pdb.png|pregnancy_AU=D|alt=|caption=度伐利尤单抗（浅绿色）与PD-L1（粉色）的结合物。{{PDB|5X8M}}|mab_type=mab|source=u|target=[[CD274|CD274]]|tradename=Imfinzi（英飞凡）|Drugs.com={{drugs.com|monograph|durvalumab}}|MedlinePlus=a617030|DailyMedID=Durvalumab|pregnancy_AU_comment=<ref name="Drugs.com pregnancy">{{cite web | title=Durvalumab (Imfinzi) Use During Pregnancy | website=Drugs.com | date=30 August 2019 | url=https://www.drugs.com/pregnancy/durvalumab.html | access-date=7 February 2020 | archive-date=2021-08-29 | archive-url=https://web.archive.org/web/20210829124022/https://www.drugs.com/pregnancy/durvalumab.html | dead-url=no }}</ref>|legal_status=|pregnancy_US=N|pregnancy_US_comment=<ref name="Drugs.com pregnancy" />|pregnancy_category=|legal_AU=S4|legal_CA=|legal_UK=POM|legal_US=Rx-only|legal_US_comment=<ref name="Imfinzi FDA label" />|legal_EU=Rx-only|legal_EU_comment=<ref name="Imfinzi EPAR">{{cite web | title=Imfinzi EPAR | website=[[European_Medicines_Agency|European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi | access-date=30 September 2020 | archive-date=2021-08-28 | archive-url=https://web.archive.org/web/20210828065950/https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi | dead-url=no }}</ref>|drug_name=度伐利尤单抗（Durvalumab）}}'''度伐利尤单抗'''（'''Durvalumab''' <ref>{{Cite journal|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112|url=https://www.who.int/medicines/publications/druginformation/innlists/PL112.pdf|authorlink=World Health Organization|journal=WHO Drug Information|issue=4|year=2014|volume=28|access-date=2020-12-15|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828065948/https://www.who.int/medicines/publications/druginformation/innlists/PL112.pdf|dead-url=no}}</ref>，商品名'''Imfinzi'''，中文商品名'''英飞凡'''）是一种用于治疗癌症的完全人源化[[PD-1/PD-L1抑制剂|抗PD-L1单克隆抗体]]。该药由[[阿斯利康制药|阿斯利康]]全资子公司MedImmune研发。 <ref>{{Cite web|title=Approved Drugs - Durvalumab (Imfinzi)|url=https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555930.htm|accessdate=2017-05-06|author=Research|first=Center for Drug Evaluation and|work=www.fda.gov|archive-date=2017-05-08|archive-url=https://web.archive.org/web/20170508150028/https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm|dead-url=no}}</ref>它是一种人类免疫球蛋白G1κ（IgG1κ）单克隆抗体，可阻断[[PD-L1|PD-L1]]与[[細胞程式死亡-配體1|PD-1]]（CD279）。<ref name=":0">{{Cite journal|title=De-novo and acquired resistance to immune checkpoint targeting|last=Syn|first=Nicholas L|last2=Teng|first2=Michele W L|journal=The Lancet Oncology|issue=12|doi=10.1016/s1470-2045(17)30607-1|year=2017|volume=18|pages=e731–e741|pmid=29208439|last3=Mok|first3=Tony S K|last4=Soo|first4=Ross A}}</ref>
== 临床应用 ==
[[FDA|FDA]]已批准度伐利尤单抗用于某些类型的膀胱癌和肺癌：<ref name="Imfinzi FDA label">{{Cite web|title=Imfinzi- durvalumab injection, solution|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3|accessdate=30 September 2020|date=5 June 2020|work=DailyMed|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828070027/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3|dead-url=no}}</ref>

* 用于铂类化疗失败后的晚期或转移性[[膀胱癌|膀胱癌]]的治疗。
* 用于铂类化疗联合放疗失败的III期非小细胞肺癌的治疗。
* 与[[依托泊苷|依托泊苷]]和[[卡铂|卡铂]]或[[顺铂|顺铂]]联合使用，用于晚期[[小细胞肺癌|小细胞肺癌]]的一线治疗。
[[NMPA|NMPA]]于2019年12月批准该药用于铂类化疗联合放疗失败的III期非小细胞肺癌的治疗。<ref>{{Cite web|title=阿斯利康PD-L1抑制剂度伐利尤单抗注射液在华获批|url=https://www.astrazeneca.com.cn/zh/media/press-releases/2019/_pd-l1_.html|date=2019-12-12|work=阿斯利康中国}}</ref>

== 临床试验 ==
度伐利尤单抗的ⅠB期临床试验结果表明该药对非小细胞肺癌（NSCLC）具有抑制作用，<ref name="NSCLC2016">{{Cite web|title=Astrazeneca's combination of durvalumab with tremelimumab shows clinical activity in non-small cell lung cancer irrespective of PD-L1 status. Feb 2016|url=http://seekingalpha.com/pr/16108396-astrazeneca-s-combination-durvalumab-tremelimumab-shows-clinical-activity-non-small-cell-lung|publisher=|access-date=2020-12-15|archive-date=2016-02-15|archive-url=https://web.archive.org/web/20160215164751/http://seekingalpha.com/pr/16108396-astrazeneca-s-combination-durvalumab-tremelimumab-shows-clinical-activity-non-small-cell-lung}}</ref>该药另一项关于晚期转移性膀胱癌适应症的Ⅰ期临床试验则被FDA纳入快速审批通道。<ref name=":0">{{Cite journal|title=De-novo and acquired resistance to immune checkpoint targeting|last=Syn|first=Nicholas L|last2=Teng|first2=Michele W L|journal=The Lancet Oncology|issue=12|doi=10.1016/s1470-2045(17)30607-1|year=2017|volume=18|pages=e731–e741|pmid=29208439|last3=Mok|first3=Tony S K|last4=Soo|first4=Ross A}}</ref><ref>[http://www.streetinsider.com/Corporate+News/AstraZenecas+(AZN)+Durvalumab+Granted+FDA+Breakthrough+Therapy+Designation/11329642.html AstraZeneca's (AZN) Durvalumab Granted FDA Breakthrough Therapy Designation] {{Wayback|url=http://www.streetinsider.com/Corporate+News/AstraZenecas+(AZN)+Durvalumab+Granted+FDA+Breakthrough+Therapy+Designation/11329642.html |date=20210828070013 }}. StreeInsider.com Corporate News, FDA, Management Comments. 17 February 2016.</ref>度伐利尤单抗联合[[吉非替尼|吉非替尼]]治疗小细胞肺癌的Ⅰ期临床试验结果表明该联合用药方案具有很好的疗效。<ref>{{Cite web|title=Promising Drug for Lung Cancer and Mesothelioma Patients|url=https://www.mesotheliomahelp.org/2016/05/clinical-trial-points-promising-drug-combo-lung-cancer-mesothelioma-patients-42357/|date=19 May 2016|publisher=|access-date=2020-12-15|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828070022/https://www.mesotheliomahelp.org/treatment/clinical-trials/promising-drug-lung-cancer-mesothelioma/|dead-url=no}}</ref>目前，该药正在进行一项与TLR 7/8激动剂（MEDI 9197）联合治疗实体瘤的Ⅰ期临床试验<ref>{{ClinicalTrialsGov|NCT02556463|A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors}}</ref>以及一项与[[HPV疫苗|HPV疫苗]]（MEDI 0457）联合治疗HPV相关的复发/转移性[[頭頸癌|头颈癌]]的Ⅱ期临床试验。<ref>{{ClinicalTrialsGov|NCT03162224?|Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer}}</ref>

2017年7月，阿斯利康宣布，度伐利尤单抗用于非小细胞肺癌一线治疗的Ⅲ期临床试验未能达到预期终点。 <ref>{{Cite web|title=AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer|url=https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html|work=www.astrazeneca.com|access-date=2020-12-15|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828065958/https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html|dead-url=no}}</ref>

2017年11月，Ⅲ期双盲临床试验表明了度伐利尤单抗对III期非小细胞肺癌具有一定疗效。<ref>{{Cite web|title=AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress|url=https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html|date=Sep 2017|work=www.astrazeneca.com|publisher=|access-date=2020-12-15|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828070035/https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html|dead-url=no}}</ref>

== 参考文献 ==
{{Reflist|2}}

== 外部链接 ==
* {{Cite web|title=Durvalumab|url=https://druginfo.nlm.nih.gov/drugportal/name/durvalumab|work=Drug Information Portal|publisher=U.S. National Library of Medicine|access-date=2020-12-15|archive-date=2021-12-12|archive-url=https://web.archive.org/web/20211212031948/https://druginfo.nlm.nih.gov/drugportal/name/Durvalumab}}
* {{Cite web|title=Durvalumab|url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/durvalumab|work=NCI Drug Dictionary|publisher=National Cancer Institute|access-date=2020-12-15|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828065959/https://www.cancer.gov/publications/dictionaries/cancer-drug/def/durvalumab|dead-url=no}}
* {{Cite web|title=Durvalumab|url=https://www.cancer.gov/about-cancer/treatment/drugs/durvalumab|work=National Cancer Institute|access-date=2020-12-15|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828070004/https://www.cancer.gov/about-cancer/treatment/drugs/durvalumab|dead-url=no}}
{{Extracellular chemotherapeutic agents|state=collapsed}}
{{阿斯利康制药|state=collapsed}}
[[Category:单克隆抗体类|Category:单克隆抗体类]]
[[Category:突破療法|Category:突破療法]]
[[Category:阿斯利康制药|Category:阿斯利康制药]]